Dyslipidemias
Conditions
Brief summary
To observe the effiacay, safety and risk of developing diabetes, review the patients chars who had administrated or neet to administrate the Pravafenix cap for enroll period, it is an prospective observational study that only collect the collectable information follwoing the hospital visiting date from enroll point to information collecting date. There is no extra visit for this study. Observe the data which has been collected for 3 yearts every year from enroll point, if the patients agree to be participated in this study and are suitable in inclusion/exclusion criteria. If the lipid-lowering drugs(only Ezetimibe is possible) is add-on the Pravafenix Cap administrating period, it will be analyzed by laering analysis separately. But, the reason why it is add-on to have to be written on e-CRF.
Interventions
None listed
Sponsors
Yooyoung Pharmaceutical Co., Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Among the patients with artheriosclerotic cardiovascular heart failure who have been hopitalized or visited the hospital. 1. Men or Women over 20 years old 2. Patients who had already administrated or need to administrate the Pravafenix Cap 3. Patients who have abnormal opinion(dyslipidemia) about LDL-C, TG, HDL-C at the enroll point * 70mg/dL ≤ LDL-C ≤ 160mg/dL * 150mg/dL ≤ TG ≤ 500mg/dL or HDL-C \< 40mg/dL(Men), 50mg/dL(Women) 4. Voluntary written informed consent to study participation
Exclusion criteria
1. Patient who have hypersensitivity about Pravafenix Cap or ingredients of the Pravafenix Cap. 2. Patients suffer from liver disease (Biliary cirrhosis, activated hepatophay or lasting potentiation of the transaminase 3 times excess from normal valus(which has no cause). 3. Patients suffer from kidney disease(CCR \< 60ml/min) 4. Patients have photo-allergy (allergic reaction causeed by sunlight or exposure to UV light) or phototoxic reactions (damage to skin caused by exposure to sunlight or UV light) during treatment with fibrates(lipid-modifying medicines) or ketoprofen (an anti-inflammatory medicine that can be used orally or on the skin for muscle and bone disorders, and orally for gout or period pain). 5. Acute or chronic patients who have high triglycerides academia. 6. Pregnant or breat-feeding 7. Someone who have a history of muscle problems during treatment with cholesterol-controlling medicines called 'statins' (such as simvastatin, atorvastatin, pravastatin or rosuvastatin) or fibrates (such as fenofibrate and bezafibrate). 8. Pateints who have uncontrolled hypothyroidism or hyperthyroidism. 9. Patinets who couldn't be participated in the study by the other opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence and mortaity about the cardiovascular disease case for 3 years from administrating the Pravafenix Cap. | For 3 years | (Occurence of the MACE for 3 years after aministrating the Pravfenix Cap) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Variation of the diabetic index (Before/after the administration of the Pravafenix Cap) | For 3 years | FBS, HbA1c |
| Variation of lipid parameter(Before/after the administration of the Pravafenix Cap) | For 3 years | TC, LDL-C, TG, HDL-C |
| Variation of inflammatory index(Before/after the administration of the Pravafenix Cap) | For 3 years | hs-CRP |
| Occurrence of the major clinical events | For 3 years | eventsBefore/after the administration of the Pravafenix Cap. |
Countries
South Korea
Contacts
Primary ContactMin-Kyung Kwon, Manager
Backup ContactSeul-Gi Ha, Ass. Manager
Outcome results
None listed